OIPE WOLLD

01-05-06

ZIW/sy

AMENDMENT TRANSMITTAL LETTER

Docket No. 03818/100L651-US1

Application No. Filing Date Examiner Art Unit 10/615,010-Conf. #8179 July 7, 2003 E. Peselev 1623

Applicant(s): Mladen Mercep et al.

Invention: NOVEL NONSTEROIDAL ANTI-INFLAMMATORY SUBSTANCES, COMPOSITIONS AND METHODS FOR THEIR USE

TO THE COMMISSIONER FOR PATENTS

CLAIMS AS AMENDED

Transmitted herewith is an amendment in the above-identified application.

The fee has been calculated and is transmitted as shown below.

	Claims Remaining After Amendment	Highest Number Previously Paid	Number Extra Claims Present	F	Rate	
Total Claims	45	- 43 =	2	х	50.00	100.00
ndependent Claims	29	- 27 =	2	х	200.00	400.00
/lultiple Depend	lent Claims (ch	eck if applicabl	le)			
Other fee (pleas	e specify): E	xtension for res	ponse within s	econd mo	onth	450.00
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT:						950.00
x Large Entity Small Entity						
=	al fee is require	d for this amer	ndment	لحبيسا		
A check in the Payment by The Director	copy of this she ne amount of \$ credit card. Fo r is hereby auth d below. A dup	450.00 orm PTO-2038 orized to char	to cover is attached.	Deposit	Account N	
	ny overpaymer	, ,				
	any additional fill		on processing t		•	37 CFR 1.16 and 1.17. January 3, 2006
Attorney Reg. N						
DARBY & DAR P.O. Box 5257 New York, New (212) 527-7770	York 10150-5	5257				



Docket No.: 03818/100L651-US1

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Mladen Mercep et al.

Application No.: 10/615,010

Filed: July 7, 2003

Art Unit: 1623

For: NOVEL NONSTEROIDAL ANTI-

INFLAMMATORY SUBSTANCES, COMPOSITIONS AND METHODS FOR

THEIR USE

Examiner: E. Peselev

AMENDMENT IN RESPONSE TO OFFICIAL ACTION

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

INTRODUCTORY COMMENTS

In response to the Office Action dated August 2, 2005, rejecting claims 1, 2 and 5-45, please amend the above-identified U.S. patent application as follows:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 39 of this paper.

01/06/2006 RMEBRAHT 00000030 10615010

01 FC:1201 02 FC:1202 400.00 OP 100.00 OP